Impact BioMedical, INC. Additional Paid in Capital, Common Stock
Impact BioMedical, INC. (IBO) had Additional Paid in Capital, Common Stock of $38.11 million as of 2023-12-31, per its 10-K filed 2024-02-20.
Discontinued › Balance Sheet › Equity
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2024-02-20
- 2023-12-31: Additional Paid in Capital, Common Stock $38.11M.
- 2023-09-30: Additional Paid in Capital, Common Stock $38.11M.
- 2023-06-30: Additional Paid in Capital, Common Stock $38.06M.
- 2022-12-31: Additional Paid in Capital, Common Stock $38.11M; Additional Paid in Capital, Common Stock as first filed $38.06M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2023-12-31 | $38.11M 10-K · filed 2024-02-20 | |
| 2023-09-30 | $38.11M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $38.06M 10-Q · filed 2023-10-05 | |
| 2022-12-31 | $38.11M 10-K · filed 2024-02-20 | $38.06M 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |